Summary: Classical psychedelics such as LSD, psilocybin, and mescaline are best known for activating the 5-HT2A serotonin receptor, but new research shows their actions are far more complex. In a comprehensive profiling study, researchers tested 41 psychedelic compounds against more than 300 human receptors and found strong activity not only at serotonin sites but also across dopamine and adrenergic receptors, revealing a broad polypharmacology that may underlie both therapeutic and perceptual effects.
The study further demonstrates that these compounds engage multiple intracellular signaling pathways downstream of key receptors, suggesting routes to separate therapeutic benefits from hallucinogenic effects. These findings refine our understanding of psychedelic pharmacology and point toward more targeted, precision approaches for clinical use.
Key Facts:
- Psychedelics show activity across nearly all serotonin receptor subtypes and extend to dopamine and adrenergic receptors.
- LSD, psilocybin, and mescaline activate multiple signaling pathways downstream of the 5-HT2A receptor.
- This broad receptor engagement likely contributes to both therapeutic outcomes and perceptual effects, opening possibilities for targeted drug design.
Source: Neuroscience News
Background: Classical psychedelics—including lysergamides (LSD), tryptamines (psilocybin), and phenethylamines (mescaline)—have re-emerged in mainstream neuroscience for their potential to treat depression, anxiety, PTSD, and substance use disorders. Once sidelined by cultural stigma, these molecules are now the focus of rigorous pharmacological and clinical research aimed at understanding how they alter mood, cognition, and perception.
Despite promising clinical signals, the molecular basis for their therapeutic and perceptual effects has remained only partially resolved. To address this, researchers conducted an extensive pharmacological screen of 41 classical psychedelics to map their receptor targets and downstream signaling profiles in human systems.
Beyond the 5-HT2A Receptor
The 5-HT2A receptor has long been considered central to psychedelic effects: it is abundant across cortical regions and blocking it suppresses many perceptual and cognitive alterations induced by psychedelics. However, the new study profiled these compounds against 318 human G-protein-coupled receptors (GPCRs) to produce a far broader view of their pharmacology. In addition, LSD was tested against over 450 human kinases to assess potential effects on intracellular regulation.
Results show potent, efficacious action across almost every serotonin receptor subtype and significant activity at numerous dopamine and adrenergic receptors. This polypharmacology suggests the subjective and therapeutic effects of psychedelics arise from interactions among multiple receptor systems: dopaminergic engagement may influence mood and motivation, while adrenergic activity could affect arousal and attention.
Mapping Signaling Pathways
A notable finding is that psychedelics do more than simply activate receptors; they bias signaling through distinct intracellular pathways. Using assays that measure activity of different transducers, the team found that psychedelics stimulate multiple downstream effectors of 5-HT2A, including various G proteins and β-arrestin pathways. The extent to which a compound engaged these transducers correlated with its potency and behavioral effects in animal models.
This signaling bias is important because it raises the possibility of dissociating therapeutic effects from hallucinogenic ones. If specific downstream pathways mediate antidepressant or anxiolytic actions while others drive perceptual changes, drug design could aim to favor beneficial signaling profiles—paving the way for non-hallucinogenic or lower-intensity therapeutics that retain clinical efficacy.
Why Multi-Target Activity Matters
Why do psychedelics hit so many targets? One explanation is that complex psychiatric conditions involve dysregulation across multiple neurotransmitter systems—serotonin, dopamine, and norepinephrine among them—so compounds that modulate several systems at once may produce broader or more robust therapeutic effects than single-target drugs. Another possibility is that coordinated receptor engagement contributes to profound subjective experiences such as ego dissolution and enhanced emotional processing, which many researchers believe facilitate psychological change and healing.
Toward Precision Psychedelic Medicine
Although many psychedelics share 5-HT2A activity, their overall receptor fingerprints differ substantially, which can explain variations in potency, duration, and clinical profile. For example, LSD’s unusually long duration and high potency may stem from stronger binding not only at 5-HT2A but also at specific dopaminergic and adrenergic receptors. By charting these pharmacological fingerprints, scientists can better match compounds to clinical indications or engineer novel molecules that maximize therapeutic outcomes while minimizing unwanted effects.
These findings align with ongoing efforts to develop next-generation psychedelics that are more selective, better tolerated, and easier to administer in therapeutic settings—efforts that will rely on detailed receptor and signaling maps like those generated in this study.
The Road Ahead
This comprehensive pharmacological analysis underscores the complexity of brain signaling and highlights how much remains to be learned about how psychedelics produce their effects. As clinical trials expand for depression, PTSD, addiction, and other conditions, understanding the molecular mechanisms of these drugs is essential for safely unlocking their therapeutic potential.
By revealing multiple receptor and signaling targets, the study lays groundwork for precision psychedelic medicine—an approach that could transform treatment for some of the most challenging mental health disorders by tailoring compounds to specific therapeutic pathways.
In short: psychedelics are more than simple serotonin agonists. They are multifunctional molecular tools that engage a symphony of receptors and intracellular pathways, collectively shaping the profound shifts in mood, thought, and perception that researchers and clinicians are now investigating.
About this psychopharmacology and neuroscience research news
Author: Neuroscience News Communications
Source: Neuroscience News
Contact: Neuroscience News Communications – Neuroscience News
Image: The image is credited to Neuroscience News
Original Research: Closed access.
“The polypharmacology of psychedelics reveals multiple targets for potential therapeutics” by Manish K. Jain et al., Neuron. DOI: 10.1016/j.neuron.2025.06.012
Abstract
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
The classical psychedelics (+)-lysergic acid diethylamide (LSD), psilocybin, and mescaline exert psychedelic effects via activation of the 5-HT2A serotonin receptor (5-HT2AR). Recent clinical studies suggest these compounds may also offer therapeutic benefits for conditions including depression, anxiety, migraine, substance use disorders, and post-traumatic stress disorder.
In this study, researchers profiled 41 classical psychedelics from tryptamine, phenethylamine, and lysergamide classes against 318 human GPCRs to map target profiles, and assessed LSD against more than 450 human kinases. They found potent, efficacious actions at nearly every serotonin, dopamine, and adrenergic receptor and quantified activation across multiple intracellular transducers. Psychedelics stimulate several 5-HT2A transducers, each correlating with psychedelic-like actions in vivo, indicating that multiple molecular targets collectively contribute to their effects.